Avinger Inc AVGR
We take great care to ensure that the data presented and summarized in this overview for Avinger Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AVGR
Top Purchases
Top Sells
About AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Transactions at AVGR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 18
2024
|
Jeffrey M Soinski Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,254
-35.36%
|
$64,508
$2.73 P/Share
|
Jan 18
2024
|
Jeffrey M Soinski Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,071
+44.82%
|
-
|
Jan 18
2024
|
Himanshu Patel Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,616
-37.36%
|
$49,232
$2.73 P/Share
|
Jan 18
2024
|
Himanshu Patel Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,553
+45.74%
|
-
|
Jan 11
2024
|
James B Mcelwee Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,597
+46.13%
|
-
|
Jan 11
2024
|
Tamara Elias Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,597
+46.07%
|
-
|
Jan 11
2024
|
James Cullen Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,597
+46.13%
|
-
|
Mar 23
2023
|
Nabeel Paul Subainati Vice President, Finance |
SELL
Open market or private sale
|
Direct |
223
-0.26%
|
$0
$0.81 P/Share
|
Mar 22
2023
|
Nabeel Paul Subainati Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
417
+0.48%
|
-
|
Jan 18
2023
|
Jeffrey M Soinski Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+49.3%
|
-
|
Jan 18
2023
|
Nabeel Paul Subainati Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+49.86%
|
-
|
Jan 18
2023
|
James Cullen Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,976
+48.61%
|
-
|
Jan 18
2023
|
Himanshu Patel Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+49.17%
|
-
|
Jan 18
2023
|
James B Mcelwee Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,976
+48.61%
|
-
|
Jan 18
2023
|
Tamara Elias Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,976
+48.22%
|
-
|
Sep 18
2022
|
Jeffrey M Soinski Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+15.02%
|
-
|
Sep 18
2022
|
Himanshu Patel Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+14.08%
|
-
|
Sep 10
2022
|
Tamara Elias Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+33.33%
|
-
|
Nov 30
2021
|
James Cullen Director |
SELL
Open market or private sale
|
Direct |
184
-0.26%
|
$0
$0.57 P/Share
|
Nov 24
2021
|
James Cullen Director |
SELL
Open market or private sale
|
Direct |
32
-0.05%
|
$0
$0.62 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 206K shares |
---|
Payment of exercise price or tax liability | 56.9K shares |
---|